Dendritic cell-derived exosomes as immunotherapies in the fight against cancer

Journal of Immunology

Volumn 193, Issue 3, 2014, Pages 1006-1011

  Pitt, Jonathan M ^a,b   Charrier, Mélinda ^a,b   Viaud, Sophie ^a,b   André, Fabrice ^a,b   Besse, Benjamin ^a,b   Chaput, Nathalie ^a,b   Zitvogel, Laurence ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAMBETA2 INTEGRIN; CANCER VACCINE; CYCLOPHOSPHAMIDE; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; LACTADHERIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; BIOGENESIS; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CHEMICAL COMPOSITION; DENDRITIC CELL DERIVED EXOSOME; DRUG POTENTIATION; EXOSOME; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR DERIVED EXOSOME;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EXOSOMES; HUMANS; IMMUNOTHERAPY; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 84906098610     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400703     Document Type: Review

References (48)

1. Thery, C., M. Ostrowski, and E. Segura. 2009. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9: 581-593.
2. Raposo, G., and W. Stoorvogel. 2013. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200: 373-383.
3. Harding, C. V., J. E. Heuser, and P. D. Stahl. 2013. Exosomes: looking back three decades and into the future. J. Cell Biol. 200: 367-371.
4. Robbins, P. D., and A. E. Morelli. 2014. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14: 195-208.
5. Wolfers, J., A. Lozier, G. Raposo, A. Regnault, C. Thery, C. Masurier, C. Flament, S. Pouzieux, F. Faure, T. Tursz, et al. 2001. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7: 297-303.
6. Peinado, H., M. Alečković, S. Lavotshkin, I. Matei, B. Costa-Silva, G. Moreno-Bueno, M. Hergueta-Redondo, C. Williams, G. García-Santos, C. Ghajar, et al. 2012. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat. Med. 18: 883-891.
7. Hood, J. L., R. S. San, and S. A. Wickline. 2011. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71: 3792-3801.
8. Al-Nedawi, K., B. Meehan, J. Micallef, V. Lhotak, L. May, A. Guha, and J. Rak. 2008. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10: 619-624.
9. Skog, J., T. Würdinger, S. van Rijn, D. H. Meijer, L. Gainche, M. Sena-Esteves, W. T. Curry, Jr., B. S. Carter, A. M. Krichevsky, and X. O. Breakefield. 2008. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10: 1470-1476.
10. Yang, C., S. H. Kim, N. R. Bianco, and P. D. Robbins. 2011. Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model. PLoS ONE 6: e22517.
11. Yang, C., M. A. Ruffner, S. H. Kim, and P. D. Robbins. 2012. Plasma-derived MHC class II+ exosomes from tumor-bearing mice suppress tumor antigen-specific immune responses. Eur. J. Immunol. 42: 1778-1784.
12. Liu, C., S. Yu, K. Zinn, J. Wang, L. Zhang, Y. Jia, J. C. Kappes, S. Barnes, R. P. Kimberly, W. E. Grizzle, and H. G. Zhang. 2006. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176: 1375-1385.
13. Yu, S., C. Liu, K. Su, J. Wang, Y. Liu, L. Zhang, C. Li, Y. Cong, R. Kimberly, W. E. Grizzle, et al. 2007. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178: 6867-6875.
14. Xiang, X., A. Poliakov, C. Liu, Y. Liu, Z. B. Deng, J. Wang, Z. Cheng, S. V. Shah, G. J. Wang, L. Zhang, et al. 2009. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 124: 2621-2633.
15. Zhang, H. G., X. Zhuang, D. Sun, Y. Liu, X. Xiang, and W. E. Grizzle. 2012. Exosomes and immune surveillance of neoplastic lesions: a review. Biotech. Histochem. 87: 161-168.
16. Logozzi, M., A. De Milito, L. Lugini, M. Borghi, L. Calabro, M. Spada, M. Perdicchio, M. L. Marino, C. Federici, E. Iessi, et al. 2009. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE 4: e5219.
17. Andre, F., N. E. Schartz, M. Movassagh, C. Flament, P. Pautier, P. Morice, C. Pomel, C. Lhomme, B. Escudier, T. Le Chevalier, et al. 2002. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360: 295-305.
18. Chaput, N., J. Taieb, N. E. Schartz, F. André, E. Angevin, and L. Zitvogel. 2004. Exosome-based immunotherapy. Cancer Immunol. Immunother. 53: 234-239.
19. Thery, C., M. Boussac, P. Véron, P. Ricciardi-Castagnoli, G. Raposo, J. Garin, and S. Amigorena. 2001. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166: 7309-7318.
20. Thery, C., A. Regnault, J. Garin, J. Wolfers, L. Zitvogel, P. Ricciardi-Castagnoli, G. Raposo, and S. Amigorena. 1999. Molecular characterization of dendritic cellderived exosomes. Selective accumulation of the heat shock protein hsc73. J. Cell Biol. 147: 599-610.
21. Raposo, G., H. W. Nijman, W. Stoorvogel, R. Liejendekker, C. V. Harding, C. J. Melief, and H. J. Geuze. 1996. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183: 1161-1172.
22. Zitvogel, L., A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza, P. Ricciardi-Castagnoli, G. Raposo, and S. Amigorena. 1998. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4: 594-600.
23. Admyre, C., S. M. Johansson, S. Paulie, and S. Gabrielsson. 2006. Direct exosome stimulation of peripheral human T cells detected by ELISPOT. Eur. J. Immunol. 36: 1772-1781.
24. Utsugi-Kobukai, S., H. Fujimaki, C. Hotta, M. Nakazawa, and M. Minami. 2003.MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol. Lett. 89: 125-131.
25. André, F., N. Chaput, N. E. Schartz, C. Flament, N. Aubert, J. Bernard, F. Lemonnier, G. Raposo, B. Escudier, D. H. Hsu, et al. 2004. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 172: 2126-2136.
26. Vincent-Schneider, H., P. Stumptner-Cuvelette, D. Lankar, S. Pain, G. Raposo, P. Benaroch, and C. Bonnerot. 2002. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int. Immunol. 14: 713-722.
27. Thery, C., L. Duban, E. Segura, P. Véron, O. Lantz, and S. Amigorena. 2002. Indirect activation of naïlve CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. 3: 1156-1162.
28. Muntasell, A., A. C. Berger, and P. A. Roche. 2007. T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes. EMBO J. 26: 4263-4272.
29. Montecalvo, A., W. J. Shufesky, D. B. Stolz, M. G. Sullivan, Z. Wang, S. J. Divito, G. D. Papworth, S. C. Watkins, P. D. Robbins, A. T. Larregina, and A. E. Morelli. 2008. Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J. Immunol. 180: 3081-3090.
30. Viaud, S., M. Terme, C. Flament, J. Taieb, F. André, S. Novault, B. Escudier, C. Robert, S. Caillat-Zucman, T. Tursz, et al. 2009. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS ONE 4: e4942.
31. Simhadri, V. R., K. S. Reiners, H. P. Hansen, D. Topolar, V. L. Simhadri, K. Nohroudi, T. A. Kufer, A. Engert, and E. Pogge von Strandmann. 2008. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS ONE 3: e3377.
32. Munich, S., A. Sobo-Vujanovic, W. J. Buchser, D. Beer-Stolz, and N. L. Vujanovic. 2012. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. OncoImmunology 1: 1074-1083.
33. Tamura, Y., T. Torigoe, K. Kukita, K. Saito, K. Okuya, G. Kutomi, K. Hirata, and N. Sato. 2012. Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity. Immunotherapy 4: 841-852.
34. Valadi, H., K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall. 2007.Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9: 654-659.
35. Montecalvo, A., A. T. Larregina, W. J. Shufesky, D. B. Stolz, M. L. Sullivan, J. M. Karlsson, C. J. Baty, G. A. Gibson, G. Erdos, Z. Wang, et al. 2012. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119: 756-766.
36. Escudier, B., T. Dorval, N. Chaput, F. André, M. P. Caby, S. Novault, C. Flament, C. Leboulaire, C. Borg, S. Amigorena, et al. 2005. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J. Transl. Med. 3: 10.
37. Morse, M. A., J. Garst, T. Osada, S. Khan, A. Hobeika, T. M. Clay, N. Valente, R. Shreeniwas, M. A. Sutton, A. Delcayre, et al. 2005. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 3: 9.
38. Chaput, N., N. E. Schartz, F. André, J. Taieb, S. Novault, P. Bonnaventure, N. Aubert, J. Bernard, F. Lemonnier, M. Merad, et al. 2004. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol. 172: 2137-2146.
39. Segura, E., C. Nicco, B. Lombard, P. Véron, G. Raposo, F. Batteux, S. Amigorena, and C. Thery. 2005. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106: 216-223.
40. Viaud, S., S. Ploix, V. Lapierre, C. Thery, P. H. Commere, D. Tramalloni, K. Gorrichon, P. Virault-Rocroy, T. Tursz, O. Lantz, et al. 2011. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-g. J. Immunother. 34: 65-75.
41. Segura, E., S. Amigorena, and C. Thery. 2005. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol. Dis. 35: 89-93.
42. Näslund, T. I., U. Gehrmann, K. R. Qazi, M. C. Karlsson, and S. Gabrielsson. 2013. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J. Immunol. 190: 2712-2719.
43. Qazi, K. R., U. Gehrmann, E. Domange Jordö, M. C. Karlsson, and S. Gabrielsson. 2009. Antigen-loaded exosomes alone induce Th1-type memory through a B-celldependent mechanism. Blood 113: 2673-2683.
44. Viaud, S., C. Thery, S. Ploix, T. Tursz, V. Lapierre, O. Lantz, L. Zitvogel, and N. Chaput. 2010. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res. 70: 1281-1285.
45. Taieb, J., N. Chaput, N. Schartz, S. Roux, S. Novault, C. Ménard, F. Ghiringhelli, M. Terme, A. F. Carpentier, G. Darrasse-Jèze, et al. 2006. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. [Published erratum appears in 2006 J. Immunol. 177: 2024.] J. Immunol. 176: 2722-2729.
46. Gehrmann, U., S. Hiltbrunner, A. M. Georgoudaki, M. C. Karlsson, T. I. Näslund, and S. Gabrielsson. 2013. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with a-galactosylceramide on exosomes. Cancer Res. 73: 3865-3876.
47. Esser, J., U. Gehrmann, F. L. D'Alexandri, A. M. Hidalgo-Estevez, C. E. Wheelock, A. Scheynius, S. Gabrielsson, and O. Radmark. 2010. Exosomes from human macrophages and dendritic cells contain enzymes for leukotriene biosynthesis and promote granulocyte migration. J. Allergy Clin. Immunol. 126: 1032-1040, 1040. e1-4.
48. Bobrie, A., S. Krumeich, F. Reyal, C. Recchi, L. F. Moita, M. C. Seabra,M. Ostrowski, and C. Thery. 2012. Rab27a supports exosome-dependent and-independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 72: 4920-4930.